REFERENCE
MHRA.Lenalidomide (Revlimid): investigation of risk of second primary malignancies in myeloma. Drug Safety Update 4: A2, No. 10, May 2011
Rights and permissions
About this article
Cite this article
Stick to licensed indications for lenalidomide. React. Wkly. 1352, 3 (2011). https://doi.org/10.2165/00128415-201113520-00007
Published:
Issue Date:
DOI: https://doi.org/10.2165/00128415-201113520-00007